Establishment of reference intervals for soluble ST2 from a United States population

Clinica Chimica Acta

Volumn 411, Issue 21-22, 2010, Pages 1825-1826

  Lu, Jun ^a   Snider, James V ^b   Grenache, David G ^a,c  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b Critical Diagnostics   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Heart failure; Reference intervals; ST2

Indexed keywords

INTERLEUKIN RECEPTOR; ST2 PROTEIN; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN STABILITY; QUANTITATIVE ANALYSIS; REFERENCE VALUE; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TEMPERATURE SENSITIVITY; UNITED STATES; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIMIT OF DETECTION; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SEX FACTORS; TEMPERATURE; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 77956477703     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.07.014     Document Type: Article

References (11)

1. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008, 7:827-840.
2. Weinberg E.O., Shimpo M., De Keulenaer G.W., et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002, 106:2961-2966.
3. Iwahana H., Yanagisawa K., Ito-Kosaka A., et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999, 264:397-406.
4. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117:1538-1549.
5. Shah R.V., Chen-Tournoux A.A., Picard M.H., van Kimmenade R.R., Januzzi J.L. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009, 2:311-319.
6. Januzzi J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007, 50:607-613.
7. Mueller T., Dieplinger B., Gegenhuber A., Poelz W., Pacher R., Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008, 54:752-756.
8. Shah R.V., Januzzi J.L. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep 2010, 7:9-14.
9. Weir R.A., Miller A.M., Murphy G.E., et al. Serum soluble ST2P: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010, 55:243-250.
10. Dieplinger B., Januzzi J.L., Steinmair M., et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chim Acta 2009, 409:33-40.
11. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.